title: Central nervous system lymphoma associated with natalizumab.
abstract: Patients with primary central nervous system lymphoma (PCNSL) after treatment with natalizumab have been considered co-incidental. We report another case of PCNSL in a patient where the explosive onset suggests a causal link.
authors.affiliation: Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia.
authors.forename: Angelika
authors.initials: A
authors.lastname: Na
authors.affiliation: Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia.
authors.forename: Nick
authors.initials: N
authors.lastname: Hall
authors.affiliation: Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia.
authors.forename: Bhadrakant
authors.initials: B
authors.lastname: Kavar
authors.affiliation: Department of Neurology, Royal Melbourne Hospital, Grattan Street, Parkville, Melbourne, VIC 3050, Australia. Electronic address: John.king@mh.org.au.
authors.forename: John
authors.initials: J
authors.lastname: King
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D016543:Central Nervous System Neoplasms / Q000139:chemically induced* / Q000175:diagnosis*; D017809:Fatal Outcome; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D000069442:Natalizumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab
keywords: Lymphoma; Multiple sclerosis; Natalizumab